These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25527978)

  • 1. Quality evaluation of the Finasteride polymorphic forms I and II in capsules.
    da Silva LM; Montanari CM; Santos OMM; Cazedey ECL; Ângelo ML; de Araújo MB
    J Pharm Biomed Anal; 2015 Feb; 105():24-31. PubMed ID: 25527978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water-stable and finasteride-loaded polyvinyl alcohol nanofibrous particles with sustained drug release for improved prostatic artery embolization - In vitro and in vivo evaluation.
    Li X; Li B; Ullah MW; Panday R; Cao J; Li Q; Zhang Y; Wang L; Yang G
    Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111107. PubMed ID: 32600710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limits of visual detection for finasteride polymorphs in prepared binary mixtures: analysis by X-ray powder diffraction.
    Antonio SG; Paiva-Santos CO; Bezzon VDN
    J Pharm Sci; 2014 Nov; 103(11):3567-3575. PubMed ID: 25197019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia.
    Kim S; Eum J; Yang H; Jung H
    J Control Release; 2019 Dec; 316():1-11. PubMed ID: 31689460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia.
    Roque LV; Dias IS; Cruz N; Rebelo A; Roberto A; Rijo P; Reis CP
    Skin Pharmacol Physiol; 2017; 30(4):197-204. PubMed ID: 28689207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive spectroscopic characterization of finasteride polymorphic forms. Does the form X exist?
    Frelek J; Górecki M; Dziedzic A; Jabłońska E; Kamieński B; Wojcieszczyk RK; Luboradzki R; Szczepek WJ
    J Pharm Sci; 2015 May; 104(5):1650-7. PubMed ID: 25648836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation.
    Ahmed TA
    Int J Nanomedicine; 2016; 11():515-27. PubMed ID: 26893559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal film-loaded finasteride microplates to enhance drug skin permeation: Two-step optimization study.
    Ahmed TA; El-Say KM
    Eur J Pharm Sci; 2016 Jun; 88():246-56. PubMed ID: 26993962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of liposomal systems of finasteride for topical applications: design, characterization, and in vitro evaluation.
    Kumar R; Singh B; Bakshi G; Katare OP
    Pharm Dev Technol; 2007; 12(6):591-601. PubMed ID: 18161632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and bioactivity of new Finasteride conjugate.
    Shuang Z; Jiazhen W; Lijuan Y; Zhuo L; Dahai Y; Jinfeng L; Jing Y; Yongtao L; En-Si W; Xuexun F
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3439-42. PubMed ID: 21515045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
    Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
    J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of polymorphic contamination in meloxicam raw materials and its effects on the physicochemical quality of drug product.
    Jacon Freitas JT; Santos Viana OMM; Bonfilio R; Doriguetto AC; de Araújo MB
    Eur J Pharm Sci; 2017 Nov; 109():347-358. PubMed ID: 28844846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of chlorthalidone polymorphs in raw materials and tablets and the effect of forms I and II on the dissolution properties of drug products.
    Bonfilio R; Leal JS; Santos OM; Pereira GR; Doriguetto AC; de Araújo MB
    J Pharm Biomed Anal; 2014 Jan; 88():562-70. PubMed ID: 24216278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
    Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
    Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
    Mady FM; Farghaly Aly U
    Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative determination of two polymorphic forms of imatinib mesylate in a drug substance and tablet formulation by X-ray powder diffraction, differential scanning calorimetry and attenuated total reflectance Fourier transform infrared spectroscopy.
    Bellur Atici E; Karlığa B
    J Pharm Biomed Anal; 2015 Oct; 114():330-40. PubMed ID: 26099262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses.
    Constanzer ML; Matuszewski BK; Bayne WF
    J Chromatogr; 1991 May; 566(1):127-34. PubMed ID: 1653258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W; Leerunyakul K; Suchonwanit P
    Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of polymorphism on the manufacturability and in vitro dissolution of sulindac-containing hard gelatin capsules.
    Guadalupe Sánchez-González E; Yépez-Mulia L; Jesús Hernández-Abad V; Jung Cook H
    Pharm Dev Technol; 2015 May; 20(3):306-13. PubMed ID: 24417644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.